Apolipoprotein e gene, environmental risk factors, and their interactions in dementia among seniors

International Journal of Geriatric Psychiatry

Volumn 28, Issue 10, 2013, Pages 1005-1014

  Meng, Xiangfei ^a   D'Arcy, Carl ^a,b  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

Alzheimer disease; apolipoprotein E; association; dementia; depression

Indexed keywords

APOLIPOPROTEIN E; APOLIPOPROTEIN E EPSILON2; APOLIPOPROTEIN E EPSILON3; APOLIPOPROTEIN E EPSILON4; UNCLASSIFIED DRUG;

AGED; ALLELE; ALZHEIMER DISEASE; ARTICLE; CLINICAL ASSESSMENT; COGNITIVE DEFECT; COGNITIVELY IMPAIRED NOT DEMENTED; DEMENTIA; DEPRESSION; DIABETES MELLITUS; EDUCATIONAL STATUS; EXERCISE; FAMILY HISTORY; FEMALE; GENETIC ASSOCIATION; GENOTYPE; GENOTYPE ENVIRONMENT INTERACTION; HUMAN; INCIDENTAL FINDING; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; MULTIINFARCT DEMENTIA; OUTCOME ASSESSMENT; RISK FACTOR;

ALZHEIMER DISEASE; APOLIPOPROTEIN E; ASSOCIATION; DEMENTIA; DEPRESSION;

AGED; ALLELES; APOLIPOPROTEIN E3; COGNITION DISORDERS; COMORBIDITY; DEMENTIA; DEPRESSION; FEMALE; GENE-ENVIRONMENT INTERACTION; GENETIC ASSOCIATION STUDIES; GENOTYPE; HEALTH STATUS; HUMANS; LIFE STYLE; LOGISTIC MODELS; MALE; RISK FACTORS;

EID: 84883553670     PISSN: 08856230     EISSN: 10991166     Source Type: Journal    
DOI: 10.1002/gps.3918     Document Type: Article

References (50)

1. Adams R, Victor M, Ropper A,. 1997. Degenerative Disease of the Nervous System. Principles of Neurology. McGraw-Hill: New York; 1049-1057.
2. Alberts MJ, Graffagnino C, McClenny C, et al,. 1995. ApoE genotype and survival from intracerebral haemorrhage. Lancet 346: 575.
3. Allan LM, Rowan EN, Firbank MJ, et al,. 2011. Long term incidence of dementia, predictors of mortality and pathological diagnosis in older stroke survivors. Brain 134: 3716-3727.
4. Andersen K, Lolk A, Kragh-Sorensen P, et al,. 2005. Depression and the risk of Alzheimer disease. Epidemiology 16: 233-238. (Pubitemid 40314416)
5. Barnes DE, Alexopoulos GS, Lopez OL, et al,. 2006. Depressive symptoms, vascular disease, and mild cognitive impairment: findings from the Cardiovascular Health Study. Arch Gen Psychiatry 63: 273-279.
6. Brommelhoff JA, Gatz M, Johansson B, et al,. 2009. Depression as a risk factor or prodromal feature for dementia? Findings in a population-based sample of Swedish twins. Psychol Aging 24: 373-384.
7. Butters MA, Young JB, Lopez O, et al,. 2008. Pathways linking late-life depression to persistent cognitive impairment and dementia. Dialogues Clin Neurosci 10: 345-357.
8. Byers AL, Yaffe K,. 2011. Depression and risk of developing dementia. Nat Rev Neurol 7: 323-331.
9. Byers AL, Covinsky KE, Barnes DE, et al,. 2011. Dysthymia and depression increase risk of dementia and mortality among older veterans. Am J Geriatr Psychiatry doi: 10.1097/JGP.0b013e31822001c1.
10. Camus V, Kraehenbuhl H, Preisig M, et al,. 2004. Geriatric depression and vascular diseases: what are the links? J Affect Disord 81: 1-16. (Pubitemid 38759321)
11. Castellano JM, Kim J, Stewart FR, et al,. 2011. Human ApoE isoforms differentially regulate brain amyloid-beta peptide clearance. Sci Transl Med 3: 89ra57.
12. Cheng D, Noble J, Tang MX, et al,. 2011. Type 2 diabetes and late-onset Alzheimer's disease. Dement Geriatr Cogn Disord 31: 424-430.
13. Cheng G, Huang C, Deng H, et al,. 2012. Diabetes as a risk factor for dementia and mild cognitive impairment: a meta-analysis of longitudinal studies. Intern Med J 42: 484-491.
14. Colaianna M, Tucci P, Zotti M, et al,. 2010. Soluble beta amyloid(1-42): a critical player in producing behavioural and biochemical changes evoking depressive-related state? Br J Pharmacol 159: 1704-1715.
15. Corder EH, Roses AD,. 1996. No increased risk of the apolipoprotein E epsilon2 allele with early-onset Alzheimer's disease. Ann Neurol 39: 414-416. (Pubitemid 26100773)
16. Corder EH, Saunders AM, Strittmatter WJ, et al,. 1993. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261: 921-923. (Pubitemid 23275809)
17. Daviglus ML, Bell CC, Berrettini W, et al,. 2010. National Institutes of Health State-of-the-Science Conference statement: preventing Alzheimer disease and cognitive decline. Ann Intern Med 153: 176-181.
18. Devanand DP, Sano M, Tang MX, et al,. 1996. Depressed mood and the incidence of Alzheimer's disease in the elderly living in the community. Arch Gen Psychiatry 53: 175-182. (Pubitemid 26049393)
19. Farrer LA, Cupples LA, Haines JL, et al,. 1997. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 278: 1349-1356. (Pubitemid 27449696)
20. Fuhrer R, Dufouil C, Dartigues JF, et al,. 2003. Exploring sex differences in the relationship between depressive symptoms and dementia incidence: prospective results from the PAQUID Study. J Am Geriatr Soc 51: 1055-1063. (Pubitemid 36993460)
21. Fumagalli F, Racagni G, Riva MA,. 2006. The expanding role of BDNF: a therapeutic target for Alzheimer's disease? Pharmacogenomics J 6: 8-15. (Pubitemid 43118305)
22. Ganguli M, Du Y, Dodge HH, et al,. 2006. Depressive symptoms and cognitive decline in late life: a prospective epidemiological study. Arch Gen Psychiatry 63: 153-160. (Pubitemid 43213876)
23. Garcia-Alloza M, Hirst WD, Chen CP, et al,. 2004. Differential involvement of 5-HT(1B/1D) and 5-HT6 receptors in cognitive and non-cognitive symptoms in Alzheimer's disease. Neuropsychopharmacology 29: 410-416. (Pubitemid 38175158)
24. Graham JE, Rockwood K, Beattie BL, et al,. 1996. Standardization of the diagnosis of dementia in the Canadian Study of Health and Aging. Neuroepidemiology 15: 246-256. (Pubitemid 26276087)
25. Irie F, Masaki KH, Petrovitch H, et al,. 2008. Apolipoprotein E epsilon4 allele genotype and the effect of depressive symptoms on the risk of dementia in men: the Honolulu-Asia Aging Study. Arch Gen Psychiatry 65: 906-912.
26. Kardaun JW, White L, Resnick HE, et al,. 2000. Genotypes and phenotypes for apolipoprotein E and Alzheimer disease in the Honolulu-Asia Aging Study. Clin Chem 46: 1548-1554.
27. Kim JM, Kim SY, Bae KY, et al,. 2010. Apolipoprotein e4 genotype and depressive symptoms as risk factors for dementia in an older korean population. Psychiatry Investig 7: 135-140.
28. Lai CL, Liu CK, Lin RT, et al,. 2007. Association of apolipoprotein E polymorphism with ischemic stroke subtypes in Taiwan. Kaohsiung J Med Sci 23: 491-497.
29. Mattson MP,. 2004. Pathways towards and away from Alzheimer's disease. Nature 430: 631-639. (Pubitemid 39061671)
30. McKhann G, Drachman D, Folstein M, et al,. 1984. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34: 939-44. (Pubitemid 14076461)
31. Meltzer CC, Smith G, DeKosky ST, et al,. 1998. Serotonin in aging, late-life depression, and Alzheimer's disease: the emerging role of functional imaging. Neuropsychopharmacology 18: 407-30. (Pubitemid 28202350)
32. Meng X, D'Arcy C,. 2012. Mortality and morbidity hazards associated with cognitive status in seniors: a Canadian population prospective cohort study. Asia Pac Psychiatry doi: 10.1111/j.1758-5872.2012.00222.x
33. Meng X, D'Arcy C, Tempier R, et al,. 2012. Survival of patients with incident dementia who had a pre-existing psychiatric disorder: a population-based 7-year follow-up study. Int J Geriatr Psychiatry 27: 683-691.
34. Mezuk B, Eaton WW, Albrecht S, et al,. 2008. Depression and type 2 diabetes over the lifespan: a meta-analysis. Diabetes Care 31: 2383-2390.
35. Middleton L, Kirkland S, Rockwood K,. 2008. Prevention of CIND by physical activity: different impact on VCI-ND compared with MCI. J Neurol Sci 269: 80-84.
36. de la Monte SM,. 2012. Contributions of brain insulin resistance and deficiency in amyloid-related neurodegeneration in Alzheimer's disease. Drugs 72: 49-66.
37. Ownby RL, Crocco E, Acevedo A, et al,. 2006. Depression and risk for Alzheimer disease: systematic review, meta-analysis, and metaregression analysis. Arch Gen Psychiatry 63: 530-538.
38. Roses AD,. 1996. Apolipoprotein E alleles as risk factors in Alzheimer's disease. Annu Rev Med 47: 387-400. (Pubitemid 26138899)
39. Saunders AM,. 2000. Apolipoprotein E and Alzheimer disease: an update on genetic and functional analyses. J Neuropathol Exp Neurol 59: 751-758.
40. Saunders AM, Strittmatter WJ, Schmechel D, et al,. 1993. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology 43: 1467-1472. (Pubitemid 23230526)
41. Scheltens P, Rockwood K,. 2011. How golden is the gold standard of neuropathology in dementia? Alzheimers Dement 7: 486-489.
42. Tapia-Arancibia L, Aliaga E, Silhol M, et al,. 2008. New insights into brain BDNF function in normal aging and Alzheimer disease. Brain Res Rev 59: 201-220.
43. The Canadian Study of Health and Aging Working Group. 1994a. Canadian Study of Health and Aging: study methods and prevalence of dementia. CMAJ 150: 899-913.
44. The Canadian Study of Health and Aging Working Group. 1994b. The Canadian Study of Health and Aging: risk factors for Alzheimer's disease in Canada. Neurology 44: 2073-2080.
45. The Canadian Study of Health and Aging Working Group. 2000. The incidence of dementia in Canada. Neurology 55: 66-73.
46. Tsai SJ,. 2003. Brain-derived neurotrophic factor: a bridge between major depression and Alzheimer's disease? Med Hypotheses 61: 110-113.
47. Verghese PB, Castellano JM, Holtzman DM,. 2011. Apolipoprotein E in Alzheimer's disease and other neurological disorders. Lancet Neurol 10: 241-52.
48. Williams JW, Plassman BL, Burke J, et al,. 2010. Preventing Alzheimer's disease and cognitive decline. Evid Rep Technol Assess (Full Rep) (193): 1-727.
49. World Health Organization. 1992. International classification of diseases and related health problems, 10th Revision. Geneva.
50. Xu PT, Li YJ, Qin XJ, et al,. 2007. A SAGE study of apolipoprotein E3/3, E3/4 and E4/4 allele-specific gene expression in hippocampus in Alzheimer disease. Mol Cell Neurosci 36: 313-331.